Trianni Mouse, a transgenic mouse R&D platform for the discovery of fully human monoclonal antibodies (mAb) will be used by San Diego Biomedical Research Institute as the research institute to support its HIV vaccine research efforts.
Trianni CEO Matthias Wabl explained that the human antibody platform is powered by a mouse that when injected with a therapy target, produces human antibodies. Depending on the terms of the license, the mice are delivered to the licensee that isolates from the mice antibodies that are drug candidates, he told us
Joanna Davies, president and CEO at SDBRI, said in a statement, “We are extremely hopeful that the Trianni Mouse will accelerate our progress towards developing a successful HIV vaccine.”
The Trianni Mouse model has been used in license agreements to advance drug discovery. Juno Therapeutics entered an agreement with Trianni in 2017 to use the mouse model to identify full-human binders for conversion to chimeric antigen receptors (CAR) as part of its engineered T cell programs.
No financial details of the agreement were disclosed.